Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
China
Anhui Provincial Hospital, Hefei, Anhui Anhui Cancer Hospital, Hefei, Anhui Beijing GoBroad Hospital, Beijing, Beijing Municipality Beijing Cancer Hospital, Beijing, Beijing Municipality Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality Fujian Cancer Hospital, Fuzhou, Fujian Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong Guangxi Medical University Cancer Hospital, Nanning, Guangxi Harbin Medical University Cancer Hospital, Harbin, Heilongjiang The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan Henan Cancer Hospital, Zhengzhou, Henan Hubei Cancer Hospital, Wuhan, Hubei Xiangyang Central Hospital, Xiangyang, Hubei The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Liaoning Cancer Hospital, Shenyang, Liaoning Qilu Hospital of Shandong University, Jinan, Shandong Shandong Cancer Hospital, Jinan, Shandong Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality Shanxi Cancer hospital, Taiyuan, Shanxi West China Hospital of Sichuan University, Chengdu, Sichuan The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Sir Run Run Shaw Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang Zhejiang Cancer Hospital, Hangzhou, Zhejiang